Comment on Golčić et al. Evaluation of Systemic Treatment Options for Gastrointestinal Stromal Tumours. Cancers 2023, 15, 4081
Round 1
Reviewer 1 Report
Comments and Suggestions for AuthorsThank you for asking me to review this. I think that the authors make a valid point that is worth publishing to highlight the difference between dose escalation and switching drugs. I agree that dose escalation shouldn't be classified as second line therapy.
Author Response
Dear reviewer, Thanks very much for taking your time to review this manuscript. We are grateful for your positive feedback.
Reviewer 2 Report
Comments and Suggestions for AuthorsI agree with the commentary, increase of imatinib should not be considered as second line therapy formally, it can be even used upfront in exon 9 KIT mutants. ESMO and NCCN definition/guidelines are correctly intepreted and cited. I propose to add the remark about the use of Italics for gene names what is not implemented in part of the original article.
Author Response
Dear reviewer, Thank you for your suggestion. We appreciate your time and effort in reviewing our manuscript. We have considered your comment and have made the necessary revision to address it. The revision has been highlighted in yellow. We hope that the revised manuscript meets your expectation and look forward to hearing from you again.
Author Response File: Author Response.docx